(CI) Cigna Corporation Company Overview

What does The Cigna Group do?

The Cigna Group is a global health services company built around two operating platforms: Evernorth Health Services and Cigna Healthcare. The company is no longer best understood as only a traditional health insurer. Its larger economic engine is Evernorth, a pharmacy, benefit-services, specialty pharmacy, and care-services platform that includes Express Scripts, Accredo, EviCore, MD Live, and related capabilities. Cigna Healthcare, meanwhile, provides employer, individual, and international health benefits, including medical, dental, behavioral, pharmacy, vision, and spending-account solutions. The official company description emphasizes a mission to improve the health and vitality of those it serves, which matters because trust, access, claims administration, and cost management are central to the model.

Why is it classified as a health services company?

Cigna sits at the intersection of health benefits, pharmacy claims, specialty drug distribution, care navigation, utilization management, and provider networks. That mix gives it several revenue lines and several regulatory exposures. For a student or analyst, the key is to separate the insurance-like business, where premiums and medical cost ratios matter, from the pharmacy and services platform, where claims volume, drug mix, rebate structures, specialty utilization, and client renewals drive economics.

How does The Cigna Group make money?

Cigna makes money from pharmacy revenues, insurance premiums, administrative fees, service fees, and investment income. In the first quarter of 2026, pharmacy revenues were the dominant source, reflecting Evernorth’s scale in pharmacy benefit services and specialty distribution. The company’s official Evernorth site describes the platform as a set of pharmacy, care, and benefit services, which is why revenue can be very large even when segment margins are much thinner than in a pure software or branded-products model.

Which revenue streams are most important?

The latest quarterly filing makes the revenue mix clear. In the quarter ended March 31, 2026, total revenues were $68.494B, including $54.037B of pharmacy revenues, $9.812B of premiums, $4.443B of fees and other revenues, and $202M of net investment income. That means the business model’s largest reported revenue line is not insurance premium revenue; it is pharmacy-related revenue tied to Evernorth’s network, home delivery, specialty, and related services.

Why did Cigna become strategically important?

Cigna’s importance comes from the way it combines payor relationships, pharmacy scale, employer distribution, and care-management tools. The current company is the result of a long transition from insurance roots into a diversified health services platform. The strategic story is not simply growth in size; it is the migration from underwriting health risk toward managing access, pharmacy costs, specialty drug complexity, and benefit design.

Which turning points still shape the company today?

1. 1792 roots
   The company traces its heritage to early insurance institutions, creating a long history of risk pooling, underwriting, and trust-based financial services.
2. 2014 brand evolution
   Cigna’s brand work emphasized health, service, and customer vitality, foreshadowing a broader services identity rather than a narrow insurer profile.
3. Express Scripts platform shift
   The addition of Express Scripts changed the strategic center of gravity by making pharmacy benefit services and specialty pharmacy core to scale, data, and client value.
4. 2024 care expansion
   Evernorth initiatives around behavioral care, GLP-1 management, biosimilars, and virtual tools increased the role of clinical navigation and specialty cost control.
5. 2025 portfolio streamlining
   Cigna completed the $4.9B sale of Medicare Advantage, Medicare Part D, Cigna Supplemental Benefits, and CareAllies to HCSC, reducing exposure to selected government-program risks.
6. 2026 leadership transition
   Brian Evanko was appointed to succeed David Cordani as CEO effective July 1, 2026, while Cordani moved to Executive Chair, preserving continuity but marking a new operating phase.

The strategic implication is that Cigna’s valuation story depends less on a single enrollment count and more on whether the combined health-benefits and Evernorth model can keep delivering cost control, customer retention, and cash flow while navigating public scrutiny of PBM economics.

Which segments matter most right now?

Evernorth is the largest revenue platform by a wide margin, while Cigna Healthcare contributes a larger share of pre-tax adjusted income relative to its revenue base in the latest quarter. In Q1 2026, Evernorth generated $58.442B of adjusted revenues and $1.466B of pre-tax adjusted income; Cigna Healthcare generated $11.477B of adjusted revenues and $1.514B of pre-tax adjusted income. That split is critical: the segment with the most revenue is not always the segment with the highest margin.

How do Evernorth and Cigna Healthcare compare?

Within Evernorth, the Q1 2026 earnings release reported $33.002B of Pharmacy Benefit Services adjusted revenue and $25.440B from Specialty and Care Services. Pharmacy Benefit Services had $394M of pre-tax adjusted income, while Specialty and Care Services had $1.072B. That contrast shows why researchers should avoid ranking importance by revenue alone: specialty and care services can carry a very different profit profile from broader claims administration.

What does the latest quarter show?

The freshest official reporting package is the first quarter of 2026. In its Q1 2026 earnings release, Cigna reported total revenues of $68.5B, shareholders’ net income of $1.7B, diluted EPS of $6.26, adjusted income from operations of $2.1B, and adjusted EPS of $7.79. Management also raised its 2026 adjusted EPS outlook to at least $30.35.

What changed versus the prior periods?

The latest Form 10-Q for the quarter ended March 31, 2026 adds the balance-sheet and cash-flow context: cash and cash equivalents were $7.040B, total assets were $153.266B, operating cash flow was $1.131B, and property and equipment purchases were $267M in the quarter.

What gives Cigna a competitive advantage?

Cigna’s competitive advantage is not a single brand slogan. It is a bundle of scale, client relationships, healthcare data, pharmacy claims infrastructure, specialty distribution, care-navigation assets, and compliance capability. The company competes in markets where switching costs can be meaningful because large employers and health plans need reliability, broad networks, member support, formulary management, and claims administration at very large scale.

Where does the moat come from?

Competitors differ by layer of the model. In health benefits, Cigna competes with large managed-care and benefits companies such as UnitedHealth Group, Elevance Health, CVS Health/Aetna, Humana, and regional Blue Cross Blue Shield plans. In pharmacy benefit and specialty services, Express Scripts competes with other large PBM platforms, including CVS Caremark and Optum Rx. The defensible element is the ability to bundle pharmacy, benefits, specialty care, and cost management for large clients without losing trust or service quality.

How financially strong is Cigna?

Cigna’s financial profile is large, profitable, and cash-generative, but it is not asset-light in the way a software company is. It carries material debt, insurance-related liabilities, receivables, goodwill, and intangible assets. In FY2025, the company reported $274.9B of revenue, $6.0B of shareholders’ net income, $8.0B of adjusted income from operations, and $9.6B of cash flow from operations in its full-year 2025 earnings release.

What do cash flow, debt, and assets imply?

Capital allocation is also part of financial strength. In 2025 Cigna repurchased 11.9M shares for about $3.6B and increased its quarterly dividend to $1.56 per share for 2026. In Q1 2026, the company paid $417M of common-stock dividends and repaid $550M of long-term debt, while not repurchasing shares during the quarter.

Who owns Cigna stock and how is governance changing?

Cigna has a one-share, one-vote common-stock structure rather than a founder-controlled dual-class system. The latest 2026 proxy statement reported 263,660,761 shares outstanding and entitled to vote as of February 23, 2026. That structure means shareholder influence is largely institutional, while executives and directors have incentive alignment through stock ownership guidelines and equity compensation.

What does the CEO transition signal?

The company’s leadership page lists Brian Evanko as President and Chief Executive Officer, with Ann Dennison as Chief Financial Officer, while the official succession filing states that Evanko was appointed CEO effective July 1, 2026 and Cordani moved to Executive Chair. The same filing gives a compensation framework for Evanko that includes a $1.3M base salary, a $2.6M annual incentive target, and a $15.1M long-term incentive target. Those details, disclosed in the CEO succession Form 8-K, matter because they show both continuity and the scale of performance-linked compensation.

What opportunities and risks could change the story?

The opportunity set is tied to specialty pharmacy, biosimilars, GLP-1 cost management, employer demand for predictable healthcare spending, behavioral care, virtual care, and international benefits. The risk set is equally specific: medical cost trend, PBM regulation, client pricing pressure, specialty drug inflation, cybersecurity, litigation, ratings, and the execution risk of portfolio changes.

Which risks are most company-specific?

PBM scrutiny is not an abstract risk. In February 2026, the FTC announced a settlement involving Express Scripts that it said could lower drug costs and resolve allegations related to insulin list-price incentives. The official FTC settlement announcement illustrates why Cigna’s pharmacy economics must be analyzed alongside regulation, public policy, and client trust.

Why does Cigna matter for valuation?

Cigna matters for valuation because consolidated revenue alone can mislead. A DCF model has to separate low-margin but massive pharmacy revenues from higher-margin health-benefit earnings, then estimate cash conversion, reinvestment, capital returns, debt capacity, and regulatory risk. The central question is not simply whether revenue grows; it is whether Evernorth can sustain profit growth while Cigna Healthcare manages medical costs and the group preserves cash flow.

Which drivers belong in a DCF model?

For comparable-company analysis, Cigna should be compared with diversified managed-care, pharmacy-benefit, and health-services peers rather than with only insurers or only distributors. Its mix includes PBM scale, specialty services, employer health benefits, international health, and run-off exposures. A clean valuation model should therefore include separate assumptions for pharmacy revenue growth, Specialty and Care Services profit contribution, Cigna Healthcare MCR, SG&A ratio, cash taxes, capex, debt, dividends, and buybacks.

What is the key takeaway from Cigna analysis?

The Cigna Group is a large, cash-generative health services company whose investment story is defined by Evernorth scale, specialty-pharmacy economics, Cigna Healthcare underwriting discipline, and regulatory trust. The company became strategically important because it combined benefits administration with pharmacy and care-management infrastructure at national scale. That structure creates purchasing leverage, data, client stickiness, and broad customer reach, but it also exposes the company to medical cost volatility, PBM scrutiny, litigation, cybersecurity risk, and changing public policy.